化疗联合吉非替尼小分子靶向疗法在肺癌患者中的疗效分析

Therapeutic Effect of Chemotherapy Combined with Gefitinib Small Molecule Targeted Therapy in Patients with Lung Cancer

目的探讨化疗联合吉非替尼小分子靶向疗法治疗肺癌的临床疗效,为临床肺癌的治疗提供理论依据。方法病例分析均为方便选取2018年1月—2019年1月在该院就诊或者疗区治疗的肺癌患者118例,按照随机分组原则,将其分为治疗组和对照组,各59例,其中对照组采用化疗,治疗组实施化疗联合吉非替尼小分子靶向疗法,对比分析两组患者的治疗效果。结果对照组患者显效20例,有效30例,总有效率为84.75%,治疗组患者显效25例,有效31例,总有效率为94.92%,治疗组效果明显优于对照组,差异有统计学意义(χ^2=5.954,P=0.026<0.05)。结论化疗联合吉非替尼小分子靶向疗法治疗肺癌疗效显著,患者血清癌细胞标志物显著下降,患者癌症病灶明显减少,消失,值得临床推广使用。

Objective To investigate the clinical efficacy of chemotherapy combined with gefitinib small molecule targeted therapy for lung cancer,and to provide a theoretical basis for the treatment of clinical lung cancer.Methods Case analysis was performed on patients about 118 case with lung cancer who were convenien ttreated in the hospital from January 2018 to January 2019.According to the principle of randomization,they were divided into treatment group and control group,59 cases each.The treatment group was treated with chemotherapy combined with gefitinib small molecule targeted therapy,and the therapeutic effects of the two groups were compared.Results The control group was effective in 20 cases,effective in 30 cases,the total effective rate was 84.75%.The treatment group was effective in 25 cases and effective in 31 cases.The total effective rate was 94.92%,the treatment group was significantly better than the control group,and the difference was statistically significant(χ^2=5.954,P=0.026<0.05).Conclusion Chemotherapy combined with gefitinib small molecule targeted therapy for lung cancer has a significant effect.The serum cancer cell markers are significantly decreased,and the cancer lesions of patients are significantly reduced and disappeared,which is worthy of clinical promotion.